Selexis and OSE Immunotherapeutics expand collaboration

Switzerland-based biotech Selexis has signed a commercial license agreement that provides French firm OSE Immunotherapeutics (OSE: EN Paris) with access to high performance research cell banks (RCBs) from the Selexis SUREtechnology Platform.

The agreement builds upon previous collaboration between the two companies as announced in November 2016 and is designed to support the advancement of the clinical development of OSE’s interleukin receptor 7 antagonist, OSE-127 (Effi-7), under development as a potential treatment for inflammatory bowel diseases, such as ulcerative colitis.

“Based on the successful completion of our initial work on the OSE-127 program, we are pleased to broaden the scope of our collaboration with OSE Immunotherapeutics,” said Marco Bocci, Selexis vice president, licensing and business development. “The broad applicability of our technology, coupled with our robust cell lines, provides our partners with the opportunity to continue working with us long-term across their drug development cycles. We look forward to helping OSE Immunotherapeutics realize the full potential of OSE-127,” Dr Bocci noted.